Pharma and BioTech Daily

Full Lp(a)HORIZON results at AHA show Novartis' pelacarsen cut Lp(a) by 78 percent with no cardiovascular benefit, as the FDA heads into a crowded month of decisions on ivonescimab, deramiocel and povetacicept. Also: Mineralys' lorundrostat holds its effect at 48 weeks, Sarepta's new CEO faces falling Elevidys sales, and Moderna raises guidance. Good morning from Pharma and Biotech Daily, the briefing on what matters in pharma and biotech. It's Monday, November 9. Since Friday, a large outc...

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of exciting advancements and strategic shifts reshaping the landscape of drug development and patient care. A noteworthy collaboration between Zealand Pharma and Generate:Biomedicines is leading the charge, aiming to revolutionize treatment for obesity and metabolic diseases. This strategic partnership, valued at a potential $1.2 b...

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories shaping the industry. Let's begin with GSK's bold move to expand its biologics capabilities. The company has announced an $800 million investment in a new biologics production facility and innovation hub in Pennsylvania. This state-of-the-art facility aims to address the increasing demand for biologic...

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling stories that highlight the dynamic nature of the industry, marked by strategic acquisitions, groundbreaking research, and significant regulatory milestones. Starting with Asahi Kasei's acquisition of Bayer spinout AiCuris for a substantial $920 million, this investment has culminated in the FDA approval of a novel her...

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and strategic shifts shaping the industry landscape. We begin with the integration of artificial intelligence into drug discovery. GSK's recent collaboration with Chai Discovery exemplifies the growing trend of using AI to transform research and development processes. By integrating AI into its drug ...